MARCO and renal cell carcinoma: Therefore, these results suggest that MARCO+ TAMs could restrain the MHC‐I machinery and compromise the antigen cross‐presentation and tumor‐recognition capacity of TAMs, thereby impeding CD8+ CTL immunity in RCC.